Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX with trastuzumab and PD-1 inhibitor for locally advanced HER2-positive or HER2-low gastric/GEJ adenocarcinoma
ChiCTR2400081665Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab, tegafur and oxaliplatin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 cohorts), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Complete pathological response. Started Mar 2024; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400081665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081665.